{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:56:09Z","timestamp":1793706969337,"version":"4.6.1"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The cytokine interleukin (IL)-1 plays a pivotal role in immune-mediated disorders, particularly in autoinflammatory diseases. Targeting this cytokine proved to be efficacious in treating numerous IL-1-mediated pathologies. Currently, three IL-1 blockers are approved, namely anakinra, canakinumab and rilonacept, and two additional ones are expected to receive approval, namely gevokizumab and bermekimab. However, there is no systematic review on the safety and efficacy of these biologics in treating immune-mediated diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate safety and efficacy of anakinra, canakinumab, rilonacept, gevokizumab, and bermekimab for the treatment of immune-mediated disorders compared to placebo, standard-of-care treatment or other biologics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The PRISMA checklist guided the reporting of the data. We searched the PubMed database between 1 January 1984 and 31 December 2020 focusing on immune-mediated disorders. Our PubMed literature search identified 7363 articles. After screening titles and abstracts for the inclusion and exclusion criteria and assessing full texts, 75 articles were included in a narrative synthesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Anakinra was both efficacious and safe in treating cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), gout, macrophage activation syndrome, recurrent pericarditis, rheumatoid arthritis (RA), and systemic juvenile idiopathic arthritis (sJIA). Conversely, anakinra failed to show efficacy in graft-versus-host disease, Sj\u00f6gren\u2019s syndrome, and type 1 diabetes mellitus (T1DM). Canakinumab showed efficacy in treating CAPS, FMF, gout, hyper-IgD syndrome, RA, Schnitzler\u2019s syndrome, sJIA, and TNF receptor-associated periodic syndrome. However, use of canakinumab in the treatment of adult-onset Still\u2019s disease and T1DM revealed negative results. Rilonacept was efficacious and safe for the treatment of CAPS, FMF, recurrent pericarditis, and sJIA. Contrarily, Rilonacept did not reach superiority compared to placebo in the treatment of T1DM. Gevokizumab showed mixed results in treating Beh\u00e7et\u2019s disease-associated uveitis and no benefit when assessed in T1DM. Bermekimab achieved promising results in the treatment of hidradenitis suppurativa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This systematic review of IL-1-targeting biologics summarizes the current state of research, safety, and clinical efficacy of anakinra, bermekimab, canakinumab, gevokizumab, and rilonacept in treating immune-mediated disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:uri>\n                      , identifier CRD42021228547.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.888392","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T01:03:31Z","timestamp":1657069411000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":131,"title":["Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders"],"prefix":"10.3389","volume":"13","author":[{"given":"Dennis D.","family":"Arnold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayla","family":"Yalamanoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Boyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.08.017","article-title":"Monogenic Autoinflammatory Disorders: Conceptual Overview, Phenotype, and Clinical Approach","volume":"146","author":"Nigrovic","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.94","article-title":"Genetics of Monogenic Autoinflammatory Diseases: Past Successes, Future Challenges","volume":"7","author":"Aksentijevich","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.1","article-title":"Immune Regulation by Glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2014.09.003","article-title":"An Overview of FDA-Approved Biologics Medicines","volume":"20","author":"Kinch","year":"2015","journal-title":"Drug Discovery Today"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biologic Basis for Interleukin-1 in Disease","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9259646","article-title":"Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations","volume":"2016","author":"Rider","year":"2016","journal-title":"Int J Cell Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01412","article-title":"Structural Basis of IL-1 Family Cytokine Signaling","volume":"10","author":"Fields","year":"2019","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4161\/mabs.3.1.13989","article-title":"Xoma 052, a Potent, High-Affinity Monoclonal Antibody for the Treatment of IL-1\u03b2-Mediated Diseases","volume":"3","author":"Owyang","year":"2011","journal-title":"MAbs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102763","article-title":"Interleukin 1\u03b1: A Comprehensive Review on the Role of IL-1\u03b1 in the Pathogenesis and Treatment of Autoimmune and Inflammatory Diseases","volume":"20","author":"Cavalli","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00433","article-title":"Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders","volume":"11","author":"Kaegi","year":"2020","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/all.14704","article-title":"Systematic Review of Safety and Efficacy of Belimumab in Treating Immune-Mediated Disorders","volume":"76","author":"Kaegi","year":"2021","journal-title":"Allergy"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.788830","article-title":"Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders","volume":"16","author":"Kaegi","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/jech.52.6.377","article-title":"The Feasibility of Creating a Checklist for the Assessment of the Methodological Quality Both of Randomised and Non-Randomised Studies of Health Care Interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Community Health"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The Prisma 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2017.1299869","article-title":"Anakinra in the Treatment of Patients With Refractory Scleritis: A Pilot Study","volume":"26","author":"Bottin","year":"2018","journal-title":"Ocul Immunol Inflammation"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial Effect of Interleukin 1 Inhibition With Anakinra in Adult-Onset Still's Disease. An Open, Randomized, Multicenter Study","volume":"39","author":"Nordstr\u00f6m","year":"2012","journal-title":"J Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217155","article-title":"Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (Consider): Phase II, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Investigator-Initiated Trial","volume":"79","author":"Kedor","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201409","article-title":"IL-1 Trap Rilonacept in Refractory Adult Onset Still's Disease","volume":"71","author":"Petryna","year":"2012","journal-title":"Ann Rheumatic Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13075-017-1222-3","article-title":"Treatment of Mucocutaneous Manifestations in Beh\u00e7et's Disease With Anakinra: A Pilot Open-Label Study","volume":"19","author":"Grayson","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra Treatment in Drug-Resistant Behcet's Disease: A Case Series","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000358125","article-title":"Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Beh\u00e7et's Disease: A Case Series","volume":"228","author":"Vitale","year":"2014","journal-title":"Dermatology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2017.1421233","article-title":"Use of Gevokizumab in Patients With Beh\u00e7et's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study","volume":"26","author":"Tugal-Tutkun","year":"2018","journal-title":"Ocul Immunol Inflammation"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew208","article-title":"Long-Term Safety Profile of Anakinra in Patients With Severe Cryopyrin-Associated Periodic Syndromes","volume":"55","author":"Kullenberg","year":"2016","journal-title":"Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2010.02.040","article-title":"Follow-Up and Quality of Life of Patients With Cryopyrin-Associated Periodic Syndromes Treated With Anakinra","volume":"157","author":"Lepore","year":"2010","journal-title":"J Pediatr"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/apa.14217","article-title":"Cryopyrin-Associated Periodic Syndrome in Early Childhood Can Be Successfully Treated With Interleukin-1 Blockades","volume":"107","author":"Eskola","year":"2018","journal-title":"Acta Paediatr"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/art.34409","article-title":"Sustained Response and Prevention of Damage Progression in Patients With Neonatal-Onset Multisystem Inflammatory Disease Treated With Anakinra: A Cohort Study to Determine Three- and Five-Year Outcomes","volume":"64","author":"Sibley","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.30149","article-title":"Efficacy and Safety of Anakinra Therapy in Pediatric and Adult Patients With the Autoinflammatory Muckle-Wells Syndrome","volume":"63","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B30","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/ar4237","article-title":"Treatment of Muckle-Wells Syndrome: Analysis of Two IL-1-Blocking Regimens","volume":"15","author":"Kuemmerle-Deschner","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"R202","DOI":"10.1186\/ar3535","article-title":"Sustained Remission of Symptoms and Improved Health-Related Quality of Life in Patients With Cryopyrin-Associated Periodic Syndrome Treated With Canakinumab: Results of a Double-Blind Placebo-Controlled Randomized Withdrawal Study","volume":"13","author":"Kon\u00e9-Paut","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/art.23687","article-title":"Efficacy and Safety of Rilonacept (Interleukin-1 Trap) in Patients With Cryopyrin-Associated Periodic Syndromes: Results From Two Sequential Placebo-Controlled Studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94838","article-title":"Rilonacept Maintains Long-Term Inflammatory Remission in Patients With Deficiency of the IL-1 Receptor Antagonist","volume":"2","author":"Garg","year":"2017","journal-title":"JCI Insight"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/art.39995","article-title":"Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"69","author":"Ben-Zvi","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217419","article-title":"Long-Term Efficacy and Safety of Canakinumab in Patients With Colchicine-Resistant Familial Mediterranean Fever: Results From the Randomised Phase III Cluster Trial","volume":"79","author":"Ozen","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-8-201210160-00003","article-title":"Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever: A Randomized Trial","volume":"157","author":"Hashkes","year":"2012","journal-title":"Ann Intern Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key402","article-title":"Anakinra for the Treatment of Acute Gout Flares: A Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Non-Inferiority Trial","volume":"58","author":"Janssen","year":"2019","journal-title":"Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the Treatment of Acute Flares in Difficult-To-Treat Gouty Arthritis: Results of a Multicenter, Phase Ii, Dose-Ranging Study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B41","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar3297","article-title":"Canakinumab Relieves Symptoms of Acute Flares and Improves Health-Related Quality of Life in Patients With Difficult-To-Treat Gouty Arthritis by Suppressing Inflammation: Results of a Randomized, Dose-Ranging Study","volume":"13","author":"Schlesinger","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for Acute Gouty Arthritis in Patients With Limited Treatment Options: Results From Two Randomised, Multicentre, Active-Controlled, Double-Blind Trials and Their Initial Extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheumatic Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab Reduces the Risk of Acute Gouty Arthritis Flares During Initiation of Allopurinol Treatment: Results of a Double-Blind, Randomised Study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheumatic Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21690","article-title":"Rilonacept (Interleukin-1 Trap) for Prevention of Gout Flares During Initiation of Uric Acid-Lowering Therapy: Results From a Phase Iii Randomized, Double-Blind, Placebo-Controlled, Confirmatory Efficacy Study","volume":"64","author":"Schumacher","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/art.33412","article-title":"Rilonacept (Interleukin-1 Trap) in the Prevention of Acute Gout Flares During Initiation of Urate-Lowering Therapy: Results of a Phase Ii Randomized, Double-Blind, Placebo-Controlled Trial","volume":"64","author":"Schumacher","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket114","article-title":"Rilonacept for Gout Flare Prevention During Initiation of Uric Acid-Lowering Therapy: Results From the Presurge-2 International, Phase 3, Randomized, Placebo-Controlled Trial","volume":"52","author":"Mitha","year":"2013","journal-title":"Rheumatol (Oxford)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131226","article-title":"Rilonacept for Gout Flare Prevention in Patients Receiving Uric Acid-Lowering Therapy: Results of Resurge, a Phase Iii, International Safety Study","volume":"41","author":"Sundy","year":"2014","journal-title":"J Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/ar4159","article-title":"Rilonacept in the Treatment of Acute Gouty Arthritis: A Randomized, Controlled Clinical Trial Using Indomethacin as the Active Comparator","volume":"15","author":"Terkeltaub","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0985","article-title":"Interleukin-1 Blockade Does Not Prevent Acute Graft-Versus-Host Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Trial of Interleukin-1 Receptor Antagonist in Allogeneic Bone Marrow Transplantation","volume":"100","author":"Antin","year":"2002","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"Mabp1 Targeting IL-1\u03b1 for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study","volume":"138","author":"Kanni","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.149922","article-title":"On-Demand Anakinra Treatment Is Effective in Mevalonate Kinase Deficiency","volume":"70","author":"Bodar","year":"2011","journal-title":"Ann Rheumatic Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/ccm.0000000000001402","article-title":"Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase Iii Trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1504-5","article-title":"An Open-Label Pilot Study of the Efficacy and Safety of Anakinra in Patients With Psoriatic Arthritis Refractory to or Intolerant of Methotrexate (Mtx)","volume":"29","author":"Jung","year":"2010","journal-title":"Clin Rheumatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/rhu.0000000000000511","article-title":"Successful Treatment of Autoimmune Disease-Associated Pyoderma Gangrenosum With the IL-1 Receptor Antagonist Anakinra: A Case Series of 3 Patients","volume":"23","author":"Beynon","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14037","article-title":"Canakinumab in Adults With Steroid-Refractory Pyoderma Gangrenosum","volume":"173","author":"Kolios","year":"2015","journal-title":"Br J Dermatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The Airtrip Randomized Clinical Trial","volume":"316","author":"Brucato","year":"2016","journal-title":"Jama"},{"key":"B58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis","volume":"384","author":"Klein","year":"2021","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199812)41:12<2196::Aid-art15>3.0.Co;2-2","article-title":"Treatment of Rheumatoid Arthritis With Recombinant Human Interleukin-1 Receptor Antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/art.10141","article-title":"Treatment of Rheumatoid Arthritis With Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, in Combination With Methotrexate: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/art.10578","article-title":"Long-Term Safety and Maintenance of Clinical Improvement Following Treatment With Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Patients With Rheumatoid Arthritis: Extension Phase of a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"46","author":"Nuki","year":"2002","journal-title":"Arthritis Rheum"},{"key":"B62","article-title":"Interleukin 1 Receptor Antagonist Anakinra Improves Functional Status in Patients With Rheumatoid Arthritis","volume":"30","author":"Cohen","year":"2003","journal-title":"J Rheumatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/art.10870","article-title":"Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist (R-Methuil-1ra), in Patients With Rheumatoid Arthritis: A Large, International, Multicenter, Placebo-Controlled Trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016014","article-title":"A Multicentre, Double Blind, Randomised, Placebo Controlled Trial of Anakinra (Kineret), a Recombinant Interleukin 1 Receptor Antagonist, in Patients With Rheumatoid Arthritis Treated With Background Methotrexate","volume":"63","author":"Cohen","year":"2004","journal-title":"Ann rheumatic Dis"},{"key":"B65","article-title":"Concomitant Medication Use in a Large, International, Multicenter, Placebo Controlled Trial of Anakinra, a Recombinant Interleukin 1 Receptor Antagonist, in Patients With Rheumatoid Arthritis","volume":"31","author":"Tesser","year":"2004","journal-title":"J Rheumatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/art.20221","article-title":"Combination Therapy With Etanercept and Anakinra in the Treatment of Patients With Rheumatoid Arthritis Who Have Been Treated Unsuccessfully With Methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B67","article-title":"Effects of Anakinra Monotherapy on Joint Damage in Patients With Rheumatoid Arthritis. Extension of a 24-Week Randomized, Placebo-Controlled Trial","volume":"31","author":"Bresnihan","year":"2004","journal-title":"J Rheumatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of Extended Treatment With Anakinra in Patients With Rheumatoid Arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann rheumatic Dis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10067-010-1654-5","article-title":"Secondary Failure to Treatment With Recombinant Human IL-1 Receptor Antagonist in Chinese Patients With Rheumatoid Arthritis","volume":"30","author":"Bao","year":"2011","journal-title":"Clin Rheumatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2011.08.020","article-title":"Regulatory Immune Responses Induced by IL-1 Receptor Antagonist in Rheumatoid Arthritis","volume":"49","author":"Niu","year":"2011","journal-title":"Mol Immunol"},{"key":"B71","first-page":"88","article-title":"A Randomised Trial Evaluating Anakinra in Early Active Rheumatoid Arthritis","volume":"34","author":"Scott","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-12-153","article-title":"Efficacy and Safety of the Human Anti-IL-1\u03b2 Monoclonal Antibody Canakinumab in Rheumatoid Arthritis: Results of a 12-Week, Phase Ii, Dose-Finding Study","volume":"12","author":"Alten","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810366","article-title":"Molecular Genetic Investigation, Clinical Features, and Response to Treatment in 21 Patients With Schnitzler Syndrome","volume":"131","author":"Rowczenio","year":"2018","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2010.493894","article-title":"Treatment of Schnitzler's Syndrome With Anakinra: Report of Three Cases and Review of the Literature","volume":"40","author":"Gran","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.045245","article-title":"Beneficial Response to Anakinra and Thalidomide in Schnitzler's Syndrome","volume":"65","author":"de Koning","year":"2006","journal-title":"Ann Rheumatic Dis"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.07.041","article-title":"Efficacy and Safety of Canakinumab in Schnitzler Syndrome: A Multicenter Randomized Placebo-Controlled Study","volume":"139","author":"Krause","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2012.02843.x","article-title":"Efficacy and Safety of the Interleukin-1 Antagonist Rilonacept in Schnitzler Syndrome: An Open-Label Study","volume":"67","author":"Krause","year":"2012","journal-title":"Allergy"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 Inhibition and Fatigue in Primary Sj\u00f6gren's Syndrome\u2013a Double Blind, Randomised Clinical Trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PloS One"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200743","article-title":"Anakinra Treatment of Sapho Syndrome: Short-Term Results of an Open Study","volume":"71","author":"Wendling","year":"2012","journal-title":"Ann Rheumatic Dis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-0995-9","article-title":"Anakinra in the Treatment of Polyarticular-Course Juvenile Rheumatoid Arthritis: Safety and Preliminary Efficacy Results of a Randomized Multicenter Study","volume":"28","author":"Ilowite","year":"2009","journal-title":"Clin Rheumatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.134254","article-title":"A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial With the Interleukin-1 Receptor Antagonist Anakinra in Patients With Systemic-Onset Juvenile Idiopathic Arthritis (Anajis Trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheumatic Dis"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205099","article-title":"Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213150","article-title":"Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Features: Results From the 5-Year Long-Term Extension of the Phase III Pivotal Trials","volume":"77","author":"Ruperto","year":"2018","journal-title":"Ann Rheumatic Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/art.38042","article-title":"Long-Term Safety and Efficacy of Rilonacept in Patients With Systemic Juvenile Idiopathic Arthritis","volume":"65","author":"Lovell","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/art.38699","article-title":"Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/art.23475","article-title":"Persistent Efficacy of Anakinra in Patients With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)60023-9","article-title":"Interleukin-1 Antagonism in Type 1 Diabetes of Recent Onset: Two Multicentre, Randomised, Double-Blind, Placebo-Controlled Trials","volume":"381","author":"Moran","year":"2013","journal-title":"Lancet"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2016.08.005","article-title":"Interleukin-1 Antagonism in Type 1 Diabetes of Long Duration","volume":"42","author":"Seelig","year":"2016","journal-title":"Diabetes Metab"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12634","article-title":"A Phase I Study of Anti-Inflammatory Therapy With Rilonacept in Adolescents and Adults With Type 1 Diabetes Mellitus","volume":"19","author":"White","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"B90","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jaci.2013.04.008","article-title":"Efficacy and Safety of Canakinumab in Urticarial Vasculitis: An Open-Label Study","volume":"132","author":"Krause","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.jid.2019.10.024","article-title":"A Phase II Open-Label Study of Bermekimab in Patients With Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain","volume":"140","author":"Gottlieb","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580636","article-title":"Molecular Mimicry and Uveitis","volume":"11","author":"Wildner","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.888392\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T01:03:41Z","timestamp":1657069421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.888392\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":92,"alternative-id":["10.3389\/fimmu.2022.888392"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.888392","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"article-number":"888392"}}